AIM ImmunoTech (AIM) Other Non-Current Assets (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Other Non-Current Assets came in at $327000.0 in Q1 2026, down 56.11% YoY from $745000.0 in Q1 2025, and down 13.26% on a QoQ basis from $377000.0 in Q4 2025.
AIM ImmunoTech (AIM) Other Non-Current Assets (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Other Non-Current Assets data on file, last reported at $327000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 56.11% year-over-year to $327000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $327000.0 (down 56.11% YoY) and the FY2025 annual result came in at $377000.0, down 66.1% from the prior year.
- Other Non-Current Assets declined to $327000.0 in Q1 2026, from $377000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.7 million in Q3 2024 to a low of $327000.0 in Q1 2026.
- A 5-year average of $1.4 million and a median of $1.5 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 71.18% — and 2025, when it slumped 86.67%.
- Tracing AIM's Other Non-Current Assets over 5 years: stood at $1.2 million in 2022, then soared by 40.43% to $1.7 million in 2023, then sank by 34.12% to $1.1 million in 2024, then sank by 66.1% to $377000.0 in 2025, then fell by 13.26% to $327000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $327000.0 (Q1 2026), $377000.0 (Q4 2025), and $362000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 62.96 Mn |
| 10 | AIM ImmunoTech | 4.53 Mn | -5.43 Mn | 21,000.00 | 271,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 271,000.00 |
| Mar 31, 2026 | 327,000.00 |
| Dec 31, 2025 | 377,000.00 |
| Sep 30, 2025 | 362,000.00 |
| Jun 30, 2025 | 351,000.00 |
| Mar 31, 2025 | 745,000.00 |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 2.72 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 1.78 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Sep 30, 2022 | 2.14 Mn |
| Jun 30, 2022 | 1.81 Mn |
| Mar 31, 2022 | 1.51 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Sep 30, 2021 | 1.25 Mn |